← All Opthea LTD filings

Opthea LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

OPT
Opthea LTD
20-F: Opthea Discontinues Wet AMD Program, Settles Funding
Opthea Limited has ceased development of its lead drug candidate, sozinibercept, for wet AMD after Phase 3 trial failures, settling a major funding agreement and initiating a strategic review for new therapeutic applications.
OPT
Opthea LTD
20-F/A: Opthea Files Amendment to 20-F, Citing Audit Firm Signature Omission and New Certifications
Opthea Limited amends its 20-F filing to include the auditor's signature, new certifications, and minor text adjustments.
OPT
Opthea LTD
20-F: Opthea Limited Files 20-F: Details Financials, Clinical Trials, and Future Outlook
Opthea Limited's 20-F filing reveals details on financials, clinical trials for Sozinibercept, and future strategies.